Dabigatran
- TRADE NAME: Pradaxa (Boehringer Ingelheim)
- INDICATIONS: Prevention of venous thromboembolic events, reduce stroke risk
- CLASS: Anticoagulant, Thrombin inhibitor
- HALF-LIFE: 2.5 days
Amiodarone, Antacids, Anticoagulants, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Collagenase, Cyclosporine, Daclatasvir, Darunavir, Dasatinib, Deferasirox, Desirudin, Dextran, Diclofenac, Dronedarone, Fondaparinux, Heparin, Ibritumomab, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Meloxicam, Nandrolone, Neratinib, NSAIDs, P-glycoprotein inducers and inhibitors, Pantoprazole, Pentosan, Phenytoin, Polysulfate sodium, Prostacyclin analogues, Proton pump inhibitors, Quinidine, Rifampin, Rivaroxaban, Salicylates, St John's Wort, Sulfinpyrazone, Tacrolimus, Telaprevir, Thrombolytic agents, Ticlopidine, Tipranavir, Tositumomab & Iodine131, Ulipristal, Verapamil, Vitamin K antagonists
PREGNANCY CATEGORY: C
Contra-indicated in patients with active pathological bleeding or with a mechanical prosthetic heart valve.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 03/02/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric